Contradictions Unveiled: Navigating the Complexities of Plasma Center Onboarding and Revenue Growth Strategies in 2025

Record Revenue and Profitability:
- Paysign, Inc. reported record revenue of $19.1 million for Q2 2025, up 33% compared to the same period last year.
- The growth was driven by a significant improvement in gross margins and a doubling of adjusted EBITDA to $4.5 million, up 102% from the previous year.

Patient Affordability Business Expansion:
- Paysign's patient affordability business revenue grew 190% year-over-year to $7.75 million, with revenue per program rising over 83%.
- This expansion was primarily due to strong confidence from pharmaceutical partners, with over 80% more claims processed and the launch of multiple new programs.

Plasma Compensation Business Challenges:
- Plasma compensation business revenue was $10.7 million, down 4.7% year-over-year, but up 14.2% sequentially.
- The decline was due to oversupply of sourced plasma and increased collection efficiencies, although the company expects revenue growth to resume in 2026.

Strategic Growth Initiatives:
- Paysign expects to onboard an additional 10 to 13 plasma centers in the second half of the year and open a new patient services contact center in Q3.
- These initiatives are aimed at supporting expanding demand and strengthening Paysign's position in both patient affordability and plasma markets.